Skip to main content

The Intercept - July 30, 2019

KAMALA HARRIS’S PRESIDENTIAL CAMPAIGN, while releasing a new health care proposal yesterday, balked at criticism that private industry interests would seek to influence her election effort.

Ian Sams, the national press secretary for the Harris campaign, told CNN on Monday that Harris “is not taking any money from pharmaceutical executives.”

Federal Election Commission campaign finance records, however, show that the California senator has received thousands of dollars from executives at drug companies this year, most of which has not been returned.

Donors include Therese Meaney, a vice president at Endo Pharmaceuticals, a company that manufacturers opioid painkillers, who has given $1,250 to the Harris campaign; Ted Love, the president and chief executive of Global Blood Therapeutics, a startup biopharmaceutical company, who gave $2,800; J. Dana Hughes, a vice president at Pfizer, gave $250; Damian Wilmot, an executive at Vertex Pharmaceuticals, gave $1,000; and Jeffrey Stein, the chief executive of Cidara Therapeutics, another drug startup, who gave $1,000.

There has been some effort by the Harris campaign to return drug company money. Records show the campaign returned a $2,700 donation from John Guthrie, an executive at Pharmaceutics International Inc., in March, for example. Why some drug company donations were accepted and returned, while others were not, is not immediately clear. ...
Read full article at The Intercept